ROCHE DIAGNOSTICS LIMITED
Location
Founded
1956-09-14
Website
Risk Signals
24752 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ROCHE DIAGNOSTICS LIMITED
Live alerts from global media, monitored by Business Radar
2025-07-03 (luzernerzeitung.ch)
Roche Rotkreuz: Leastings in diagnostic division
The largest employer in the canton of Zug has issued dismissals at the Rotkreuz location. But how many are it? The listed group is silent.
Read more
2025-06-20 (singtaousa.com)
Northern California layoffs expand, biotech retail agriculture is hit hard | Sing Tao Daily
Northern California is facing a new wave of layoffs, covering the biotech, retail, agriculture and healthcare industries, highlighting the growing economic pressures of the region. The San Francisco Chronicle reported that the southern San Francisco biotech company Genentech, a subsidiary of Swiss pharmaceutical giant Roche, recently announced a new round of layoffs. According to the company's labor adjustment and retraining notice (WARN) data submitted to the state, it is expected to permanently cut 143 employees by mid-July. This is another manpower adjustment after laying off more than 500 employees last year. In Napa County...
Read more
2025-06-18 (stocktitan.net)
Prothena Slashes Workforce by 63% While Advancing Major Pharma Partnerships with Roche, Novo Nordisk
Prothena reduces workforce to focus on key programs and partnerships. $105M in potential milestone payments expected. See full restructuring impact and pipeline updates.
Read more
2025-06-16 (transkript.de)
Discharges: dark clouds over Switzerland?
There is a lot of good news from Switzerland on the financing page, but sometimes they are still paired with the reference to printing for cost savings. So it is at ADC Therapeutics SA from Lausanne. However, the Zurich Molecular Partners also reports a job cut in order to concentrate on clinical development by all means. Gent therapy for Duchenne Muskeldystrophy of the US Sarepta also raises questions for the global (outside USA), after the stop of the active ingredient. With the many light on the Swiss biotech scene, the dark sides are also evident.
Read more
2025-05-13 (fiercebiotech.com)
Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'
Leap is laying off half of its staff as it narrows the focus of its lead cancer drug against the backdrop of a "difficult market environment."
Read more
2025-04-14 (eleconomista.es)
Gilead and Roche cut their workforce at their California facilities
Gilead and Roche continue with the template readjustments in their facilities in California (United States). The American pharmaceutical company has eliminated 149 positions at its headquarters located in Foster City, while the Swiss laboratory has fired 108 workers in its molecular systems division in Santa Clara. These reductions will take effect at the end of May, according to Fierce Pharma.
Read more
2025-04-07 (fiercepharma.com)
In Bay Area, Gilead cuts 149 positions and Roche's diagnostics division lays off 108
Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state's Worker Adjustment and Retraining Notification (WARN) progr | Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state's Worker Adjustment and Retraining Notification (WARN) program. While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its Molecular Systems Division in Santa Clara.
Read more
2025-04-03 (bizjournals.com)
Roche's Spark Therapeutics laying off more than half its staff - Philadelphia Business Journal
The job cuts will take place in various waves at several of Spark's offices across University City.
Read more
2025-04-02 (endpts.com)
Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix
Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in California. Desentum's allergy vaccine advances. Inhibrx licenses tech. Pila develops obesity drug.
Read more
2025-03-04 (inquirer.com)
Spark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downs
The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the main asset at Spark when Roche acquired it and related layoffs.
Read more
2025-01-15 (nettavisen.no)
New code, Vaccine | Haaland invested heavily in Nykode: Now half will lose their jobs
About 40 at the vaccine company's head office in Oslo will lose their jobs.
Read more
2025-01-15 (nettavisen.no)
New code, Vaccine | Haaland invested heavily in Nykode: Now half will lose their jobs
About 40 at the vaccine company's head office in Oslo will lose their jobs.
Read more